NEWS RELEASE: Biogen-Idec will terminate its collaboration with Elan, the Dublin-based drug maker that developed Natalizumab, and buy Elan’s remaining 50% interest. Going forward, Biogen-Idec will control all marketing and distribution rights. In exchange, Biogen-Idec will make a $3.25 billion cash payment to Elan and will make future contingent payments to Elan equal to 12% of Natalizumab’s global sales for the first year. After that, Biogen-Idec will make contingent payments of 18% on annual sales of Natalizumab up to $2 billion and 25% on annual sales that exceed $2 billion.
“MS is clearly a lucrative field to be in as a pharma company. No wonder there is so much activity in the field.”
“Are you surprised how well Natalizumab is doing despite the PML scare?”